top of page
  • Active, not recruiting

NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed RRMM

Updated: Sep 24, 2022

Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5459

NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

regn 5459

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)


In the phase 1 portion of the study, the primary objectives are to assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended phase 2 dose regimen (RP2DR) of REGN5459 as monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit.


In the phase 2 portion of the study, the primary objective is to assess the preliminary anti-tumor activity of REGN5459 as measured by objective response rate (ORR).


Sponsor


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT04083534


Official Title: Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma


First Posted : September 10, 2019


Click here for details on ClinicalTrials.gov

 

Drug: REGN5459

Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459 (Code C165656)

Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5459

Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459

Anti-BCMA/CD3 Bispecific Antibody REGN5459

Anti-CD3/Anti-BCMA Bispecific Antibody REGN5459

REGN 5459

REGN-5459

REGN5459

 

Locations

United States, Indiana

United States, Michigan

United States, Minnesota

United States, New York

United States, Texas

United States, Wisconsin

 

Related Posts


NCT05164250: Compassionate Use (CU) of REGN5458 for Relapsed or Refractory Multiple Myeloma (MM)


NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM


NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM

Kommentare


Posts Archive
bottom of page